Kelsee,

I don't think I ever responded to your challenge to comment on the upcoming events. How about I take on the 10 day chunk between April 28 and May 7.

We've been talking much about the Thursday April 28th NYAS Epigenetics: Cancer and Beyond symposium, so no need to belabor that any more.

The following Monday May 2 there are two events that Resverlogix will be speaking at: Bloom Burton & Co. Healthcare Investor Conference in Toronto 11:30AM to 12 PM on May 2 (Toronto time) per the conference website and BioNetwork East in Florida (presenting on May 2 per Resverlogix events page; I don't know the time). Ken Lebioda is listed for the BioNetwork East. I don't know who is presenting in Toronta at Bloom Burton & Co.

Then May 5-7 is the ATVB/PVD conference in Nashville, TN. Resverlogix has a poster they are presenting on one of the days, though I don't know which day.

163. Apabetalone (RVX-208) Has Anti-atherosclerotic, AntiThrombotic and Anti-Inflammatory Effects in Patients With Cardiovascular Disease (CVD)

Ewelina Kulikowski, Sylwia Wasiak, Dean Gilham, Cyrus Calosing, Laura Tsujikawa, Christopher Halliday, Resverlogix Corp, Calgary, AB, Canada; Jan Johansson, Mike Sweeney, Resverlogix Corp, San Francisco, CA; Norman C Wong, Health Science Ctr., Calgary, AB, Canada

That's a loaded 10 day schedule!

BearDownAZ